ABB (~) Confirmed FY24 guidance. Trading update with total subs at March 2024 of 799k. Outperformance came from White Label.
ALL (~) No trading update. Revised their segmental disclosures.
ARB (~) Group sales for 9 months to Mar-24 are up 2.1%. Noted “the outlook is trending positively”, export order book now positive (+2.1% 3Q24).
AUB(+) Upgraded guidance to top end of A$161-$171m at FY24 UNPAT. Driven by “favorable trading momentum”
DHG(-) Trading update. Costs expected at high end of previously guided range (mid to high single digit increase from FY23). Expects EBITDA margin expansion in FY24.
FLT (~) Reaffirmed guidance for underlying FY24 PBT of $300-340m . FY24 TTV expected to surpass $23.7bn. PBT margins have improved (2% Leisure, 1.7% corporate).
GMG (+) Trading update. Has upgraded FY24 EPS from 11% to 13%. Consensus 13%
KLS (~) AAAHI performance metrics solid (100% contract retention, 70% of contract renewals pricing increase). Noted higher than average overtime being managed down. In M&T weather impacted performance in Jan/Feb.
ILU (~) No trading update. Long discussion of rare earths opportunity, arguing price levels need to lift. Claims entire market, including China, is loss-making at current levels.
IPH (~) Company has made an unsolicited, non-biding offer to acquire QIP via a Scheme of arrangement.
NEC (~) No quantitative update. Said Total TV audiences remain in growth. Subscription revenue (30% of group ex-DHG) trends from 1H have continued into 2H. Cost base being managed to the operating conditions.
PLS (~) No trading update. On the P680 Project ramp-up; “project remains on schedule and budget”
PME – Confirms NAMR TAM. Indicates a ~650m scan market in the US with PME capturing a market share of ~7%.
REG (+) Occupancy lifted to 93.9% in the March quarter up from 93.8% in the December half with an exit rate of 94.6%. Consistent with our forecast of 94.3% for the half.
PNV – First month of A$10.1m revenue in April, +69% yoy. (Street is at $130m revenue for FY25 per Bloomberg)
ALX – Reiterated CY24 DPS of A40cps.
Day 2:
AGL: (+) U/grades FY24 EBITDA to A$2,120-2,200m from A$2,025-2,175m; and NPAT to A$760-810m from A$680-780m.
NST: (+) Reaffirmed FY24 guidance.
PXA: ~ Reaffirmed FY24 guidance.
BRG: (~) Reaffirmed EBIT growth guidance. Focus on TAM opportunity.
CWY: (-) Slight downgrades at consensus EPS for FY24 despite retaining EBIT guidance
HMC: (+) Upgrades FY24 operating EPS guidance to 40¢ from 33¢ on better performance fees.
LIC: (+) Guided to strong FY25 settlements of 425-475 +50% from FY24's guidance of 300 lots (mid-point) and FY23A of 356 lots.
MPL: (~) FY24 growth guidance reaffirmed. Noted continued softness in non-surgical & extras.
GMD: (~) Re-iterated group production guidance of 130-140koz
AIA: (~) Nothing of note. Presentation outlined how passengers are returning post-Covid.
MGH: (~) Reaffirmed guidance for FY24 underlying EBITDA of $190m - $210m.
EBO: (~) No change to guide. Growth strategy discussions (base business growth, new community pharmacy revenues, cost reduction. M&A)
QAL: (~) No change to outlook and guidance [$37m-$41m NPBT]. Presentation talks to organic growth since inception, deployment pipeline, capital needs in residential development and notes
DXS: (~) Nothing new. Focus on growth profile of funds management (targeting 5:1 ratio of FUM:BS capital by 2030 vs 2.5:1 today).